Prasco announces agreement with WellSpring for the Authorized Generic of DIBENZYLINE®
Prasco intends to launch DIBENZYLINE® upon first generic entrant
“We would like to welcome WellSpring Pharmaceutical to Prasco’s expanding family of brand partners,” stated Prasco chief executive officer,
Phenoxybenzamine Hydrochloride Capsules, USP are AB-rated and substitutable for the brand DIBENZYLINE Capsules. DIBENZYLINE Capsules are indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is excessive, it may be necessary to use a beta-blocking agent concomitantly. For more information on Phenoxybenzamine Hydrochloride Capsules USP, including the prescribing information, visit prasco.com.
DIBENZYLINE is a registered trademark of WellSpring Pharmaceutical Corporation.
About WellSpring Pharmaceutical Corp. - WellSpring Pharmaceutical Corp. is a privately held pharmaceutical company founded in 1999. WellSpring has made the development, marketing and sales of niche prescription and OTC drug products its strategic focus. The firm actively acquires pharmaceutical brands and enhances their value through the development of product improvements and line extensions. The company recognizes the enduring therapeutic value of these products for smaller groups of patients. WellSpring continues to acquire, produce and market a variety of over-the-counter and prescription products in both
About Prasco Laboratories - Prasco, the Authorized Generic Company, is the privately held healthcare company located in
SOURCE Prasco Laboratories